


ADAM17 variant causes hair loss via ubiquitin ligase TRIM47 mediated degradation

Xiaoxiao Wang, ... , Hui Zhang, Ming Li

JCI Insight. 2024. <https://doi.org/10.1172/jci.insight.177588>.

Research In-Press Preview Dermatology Genetics

Graphical abstract



Find the latest version:

<https://jci.me/177588/pdf>



1 **Title:** *ADAM17* variant causes hair loss via ubiquitin ligase TRIM47 mediated
2 degradation.

3 **Author:** Xiaoxiao Wang^{1, 2, #}, Chaolan Pan^{1, 2, #}, Luyao Zheng^{1, 2, 3#}, Jianbo Wang^{4, #},
4 Quan Zou^{1, 2, #}, Peiyi Sun^{1, 2}, Kaili Zhou^{1, 2}, Anqi Zhao^{1, 5}, Qiaoyu Cao^{1, 5}, Wei He⁵,
5 Yumeng Wang^{1, 2}, Ruhong Cheng^{1, 2}, Zhirong Yao^{1, 2}, Si Zhang^{6, *}, Hui Zhang^{1, *}, Ming
6 Li^{1, 5, *}

7 1. Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University
8 School of Medicine, Shanghai 200092, China

9 2. Institute of Dermatology, Shanghai Jiaotong University School of Medicine,
10 Shanghai 200092, China

11 3. Department of Dermatology, Anhui Provincial Children's Hospital, Hefei 230051,
12 China.

13 4. Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou
14 University People's Hospital, Henan University People's Hospital, Zhengzhou
15 450003, China

16 5. Department of Dermatology, The Children's Hospital of Fudan University,
17 Shanghai 201102, China.

18 6. NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry
19 and Molecular Biology, School of Basic Medical Sciences, Fudan University,
20 Shanghai 200032, China

21 # Authors contributed equally to this work.

22 ***Correspondence:**

23 Address correspondence to: Ming Li, The Children's Hospital of Fudan University, 399
24 Wanyuan Road, Building 7#, Minhang District, Shanghai 201102, China; Phone: +86-
25 21-64931226; Email: mingli@fudan.edu.cn;

26 Address correspondence to: Hui Zhang, Xinhua Hospital, Shanghai Jiaotong University
27 School of Medicine, 1665 Kongjiang Road, Building 3#, Yangpu District, Shanghai
28 200092, China; Phone: +86-21-25076930; Email: zhanghui@xinhumed.com.cn;

29 Address correspondence to: Si Zhang, School of Basic Medical Sciences, Fudan
30 University, 137 Dong'an Road, Building West #7, Room 305, Xuhui District, Shanghai
31 200032, China; Phone: +86-21-54237223; Email: zhangsi@fudan.edu.cn.

32 **Abstract**

33 Hypotrichosis is a genetic disorder which characterized by a diffuse and progressive
34 loss of scalp and/or body hair. Nonetheless, the causative genes for several affected
35 individuals remain elusive, and the underlying mechanisms have yet to be fully
36 elucidated. Here, we discovered a dominant variant in *ADAM17* gene caused
37 hypotrichosis with woolly hair. *Adam17* (p.D647N) knock-in mice model mimicked the
38 hair abnormality in patients. *ADAM17* (p.D647N) mutation led to hair follicle stem cells
39 (HFSCs) exhaustion and caused abnormal hair follicles, ultimately resulting in alopecia.
40 Mechanistic studies revealed that ADAM17 binds directly to E3 ubiquitin ligase
41 TRIM47. *ADAM17* (p.D647N) variant enhanced the association between ADAM17 and
42 TRIM47, leading to an increase in ubiquitination and subsequent degradation of
43 ADAM17 protein. Furthermore, reduced ADAM17 protein expression affected Notch
44 signaling pathway, impairing the activation, proliferation, and differentiation of HFSCs

45 during hair follicle regeneration. Overexpression of NICD rescued the reduced
46 proliferation ability caused by *Adam17* variant in primary fibroblast cells.

47 **Keywords:** ADAM17, variant, hypotrichosis, TRIM47, HFSCs

48 **Introduction**

49 Human hair, especially human scalp hair, has important ornamental functions that are
50 essential for social communication and senses of well-being. Unwanted hair loss poses
51 psychosocial distress to affected individuals and impact on their quality of life (1). A
52 comprehensive survey conducted on individuals suffering from hair loss revealed that
53 they are more prone to experiencing anxiety, depression, and sleep disorders (2).
54 Additionally, a concerning increase in suicide rates has been found among individuals
55 suffering from hair loss (3, 4). Congenital hypotrichosis (HYPT) is a hair disorder
56 marked by sparse or complete absence of hair on the scalp and/or other body parts.
57 Occasionally, some cases accompanied by tightly coiled, curled, or woolly hair are
58 called autosomal recessive woolly hair (ARWH) or autosomal dominant woolly hair
59 (ADWH) depending on their congenital pattern (5, 6). *Keratin (KRT) 74* and *KRT71*
60 mutations are known to cause non-syndromic ADWH1 (OMIM#613981) and ADWH2
61 (OMIM#615896), respectively (7, 8). Nevertheless, the causative genes for several
62 affected individuals are still unidentified, and the underlying mechanisms have not been
63 fully comprehended.

64 ADAM17, a type I transmembrane metallopeptidase, is responsible for shedding the
65 ectodomains of over 90 substrates, including cytokines (such as TNF α), cytokine
66 receptors (such as IL-6R and TNFR), and adhesion proteins (9). It functions as a

67 molecular switch to regulate both inflammation and tissue regeneration, and is linked
68 to various inflammatory diseases, such as Alzheimer's disease, inflammation-related
69 atherosclerosis, and rheumatoid arthritis (10-12). In addition, there is compelling
70 evidence supporting the critical involvement of ADAM17 in many cancers and as
71 potential therapeutic target (13-15). Even though ADAM17 can cleave multiple
72 substrates *in vitro* or in cell-free assays, only some of them have a substantial impact
73 on development and disease *in vivo*. For instance, in skin, deletion of ADAM17 in
74 keratinocytes stimulates atopic dermatitis, driven by Th2 and/or Th17 response(s), due
75 to a selective hindrance in the recruitment of the transcription factor c-Fos to the Th2-
76 polarizing cytokine TSLP (16). ADAM17 regulates epidermal growth factor receptor
77 (EGFR) ligand-dependent terminal keratinocyte differentiation, thus preserving the
78 skin barrier (17). Additionally, ADAM17 is also involved in the development of the hair
79 follicle inner root sheath (IRS) and the establishment of hair follicle stem cells (HFSCs)
80 niche (18, 19). Despite receiving attention, further exploration is necessary to fully
81 understand the impact of ADAM17 on hair follicle development.

82 Tripartite motif-containing protein 47 (TRIM47) functions as an E3 ubiquitin ligase
83 and is involved in numerous biological processes, including tumorigenesis, cerebral
84 ischemia-reperfusion injury and endothelial inflammation (20-24). The interaction
85 between E3 ubiquitin ligase and the target protein is a core step in ubiquitin–proteasome
86 system-mediated protein degradation (25). TRIM47 aggravates lipopolysaccharide-
87 induced acute lung injury through the K63-linked ubiquitination of TRAF2 (26).
88 TRIM47 promotes tumorigenesis by facilitating the ubiquitination and subsequent

89 degradation of SMAD4, FBP1, and PKC- ϵ /PKD3 (21, 23, 27). Nevertheless, the
90 pathologic and clinical role of TRIM47 in hair follicles remain unclear.

91 In this study, we identified a variant in the CANDIS domain of *ADAM17* caused
92 autosomal dominant hypotrichosis with woolly hair. *Adam17* knock-in mouse model
93 mimicked the hair abnormality in patients. We discovered that TRIM47, an E3-
94 ubiquitin ligase, interacted with the mutant ADAM17, promoting its ubiquitination and
95 ultimate protein degradation. Eventually, reduced ADAM17 expression led to
96 dysfunction in Notch signaling pathway, which in turn contributed to hair follicle
97 malformation.

98 **Results**

99 ***ADAM17* variant leads to autosomal dominant hypotrichosis with woolly hair.**

100 We conducted a study on a Chinese family consisting of seven patients afflicted with
101 generalized hypotrichosis and curly hair. The majority of affected individuals exhibited
102 tightly curled and sparse hair either at birth or during the early stage of infancy. The
103 male patients exhibited varying degrees of hypotrichosis, often displaying fragile and
104 thin scalp hair. Notably, they also had woolly hair, patchy hair loss of eyebrows,
105 eyelashes, beard, moustache, axilla, and body. Hair growth tended to be limited, at a
106 rate of 1-2cm since birth throughout their lifetime, leading to complete hair loss as they
107 aged. Conversely, female patients presented milder symptoms in comparison to males,
108 often showing only woolly hair and punctate or flaky alopecia (**Fig. 1A**). No
109 abnormalities were detected concerning their skin, nails, teeth, or sweating.

110 Hematoxylin and eosin (HE) staining of scalp section exhibited a marked reduction in
111 hair follicle counts, with minimal inflammatory infiltration observed around hair
112 follicles (**Fig. 1B**). Scanning Electron Microscopy (SEM) imaging of healthy
113 individuals' hair revealed a consistent ceramic tile-like arrangement of hair cuticles,
114 whereas the patient displayed longitudinal grooves and cleavages. Moreover, the
115 patient's hair exhibited irregular transverse sections and widespread exfoliation of the
116 hair cuticle (**Fig. 1C**).

117 The provided pedigrees offered persuasive evidence supporting the autosomal
118 dominant mode of inheritance for the phenotypes (**Fig. 1D**). To identify potential
119 pathogenic variants associated with hypotrichosis causative genes like *KRT74*, *KRT25*,
120 *KRT71*, *APCDD1*, *RPL21*, *SNRPE*, *CDSN*, *U2HR*, *EPS8L3*, *HR*, *DSG4*, *LIPH*, *LPAR6*,
121 *DSC3*, *KRT25*, *LSS*, *TTMP*, *KRT86*, *KRT83*, and *KRT81* gene panel sequencing was
122 used. However, the variant search yielded no results. We performed a genome-wide
123 linkage analysis approach by single nucleotide polymorphisms (SNPs) and found
124 evidence for linkage to chromosome 2 with a maximum LOD score of 3.18 (**Fig. 1E**).
125 Subsequently, we narrowed down the candidate region to 19.6cM, between markers
126 rs979290 and rs57254657, which encompassed 126 annotated genes, through
127 genotyping of markers in the identified region (**Fig. S1**). We conducted the whole
128 exome sequencing on an affected member (II: 4), screening all variants in the critical
129 region, and detected a heterozygous missense mutation c.1939G>A (p. Asp647Asn) in
130 the *ADAMI7* gene (NM_003183). Upon conducting Sanger sequencing on all family
131 members, we identified that the mutation was only detected in affected family members

132 **(Fig. 1F)**. All identified variants were absent from public databases (Data ref: 1,000
133 genomes, ClinVar, Ensemble, and gnomAD) and 600 healthy controls.

134 Furthermore, ADAM17 is predominantly expressed in the hair cortex, IRS, and outer
135 root sheath (ORS) of hair follicle **(Fig. 1G, Fig. S2)**. Aspartic residue at position 647 is
136 located within the conserved ADAM17 seventeen dynamic interaction sequence
137 (CANDIS) domain of ADAM17, which is highly conserved and plays a vital role in
138 protein interactions **(Fig. 1H-I)**.

139 ***Adam17* (p.D647N) mutant mice model mimic hair loss in HYPT.**

140 In order to ascertain whether the *ADAM17* (p.D647N) mutation is pathogenic, we
141 constructed *Adam17* (p.D647N) knock-in mouse model using CRISPR/Cas9-mediated
142 genome engineering **(Fig. S3A-B)**. Homozygous mice (*Adam17*^{D647N/D647N}) were
143 distinguishable from wild-type (WT) or heterozygous littermates (*Adam17*^{D647N/+}) due
144 to their abnormal hair characteristics, including wavy vibrissa hair and a thinner, wavy
145 and gray coat **(Fig. 2A)**. These distinctive features first appeared shortly after birth and
146 gradually worsened as the mice aged **(Fig. 2A)**. Four hair follicle types with varying
147 shapes and sizes emerged during hair development in the dorsal skin of mice, which
148 including Guard (primary hair), Auchene and Awl (secondary hair) and Zigzag (tertiary
149 hair) hairs (28). Compared with the wild-type, *Adam17*^{D647N/D647N} pelages exhibited a
150 reduction in primary and secondary hairs but a significant increase in the proportion of
151 zigzag hairs. All four hair types in the *Adam17*^{D647N/D647N} pelage displayed waviness,
152 disorganized medulla, and irregular melanin piles **(Fig. 2B)**. Furthermore, scanning
153 electron microscopy reveals irregular and broken scales, suggesting a defect in the hair

154 cuticle (**Fig. 2C**).

155 HE staining showed that Adam17^{D647N/D647N} mice exhibited a diminished count of
156 hair follicles and abnormal hair architecture at the first anagen (Postnatal, P7) and the
157 second anagen (P28) (**Fig. 2D-E**). Hair follicles in wild-type mice exhibited distinctive
158 concentric layers, namely ORS, companion layer, IRS (Henle's layer, Huxley's layer,
159 and cuticle) and hair shaft (cuticle, cortex, and medulla). However, the concentric
160 structure of hair follicles in Adam17^{D647N/D647N} mice was disrupted, along with a
161 disturbed distribution of cells in the IRS (**Fig. 2D**). Additionally, hair shafts in the
162 Adam17^{D647N/D647N} mice displayed irregularities and deformities, suggesting a potential
163 role for ADAM17 in hair shaft development (**Fig. 2E**). Immunofluorescence
164 demonstrated that IRS labeled by Gata3 and hair cortex keratins labeled by the AE13
165 antibody, were markedly diminished in the hair follicles of Adam17^{D647N/D647N} mice.
166 Conversely, there was a noticeable increased expression of K5, which functioned as a
167 pivotal marker for ORS (**Fig. 2F**). Furthermore, the Ki67 immunostaining revealed a
168 decreased cell proliferation ability in hair germ of Adam17^{D647N/D647N} mice (**Fig. 2F**).
169 These observations were strengthened through western blotting (**Fig. 2G-H, Fig. S3C**).
170 In addition, Transmission Electron Microscopy (TEM) demonstrated that hair follicles
171 in wild-type mice exhibited distinctive concentric layers, while all layers apart from the
172 hair shaft and IRS cuticle of hair follicles in Adam17^{D647N/D647N} mice were
173 indistinguishable (**Fig. 2I**). Overall, these results suggested that the p.D647N mutation
174 in *ADAM17* had a substantial impact on the proper organization of hair follicles.

175 During the weaning period, Adam17^{D647N/D647N} mice exhibited a distinguishable

176 shiny, red, and semi-transparent skin phenotype. Subsequently, at P15, a notable
177 incidence of erythroderma developed along with a substantial amount of desquamation
178 (**Fig. S3D**). Ultimately, this affliction resolved spontaneously in the subsequent days.
179 Additionally, *Adam17^{D647N/D647N}* mice experienced notable developmental retardation
180 within the first four months (**Fig. S3E**). Remarkably, these mice displayed edema in
181 their extremities and a significantly high mortality rate during the peri-weaning period
182 (**Fig. S3F**). Conversely, no discernible anomalies were detected in the fur or skin of
183 *Adam17^{D647N/+}* mice as per our observation (**Fig. 2, Fig. S3**).

184 **Disruption of HFSCs in *Adam17* (p.D647N) mutant mice contributes to the woolly**
185 **hair and alopecia phenotype.**

186 To further explore whether HFs in *Adam17^{D647N/D647N}* mice are defected in forming new
187 hair, we shaved hair and monitored the appearance of skin pigmentation.
188 *Adam17^{D647N/D647N}* mice exhibited a delayed onset of anagen in partial area of dorsal
189 skin compared to their wild-type counterparts (**Fig. 3A-B**). This observation suggested
190 that the *Adam17* (p.D647N) mutation hindered hair regeneration. HFs generate a new
191 bulge besides the old one and persist to the next cycle in telogen periods, which called
192 club hair (29). HE staining demonstrated a remarkably decrease of two-bulge HFs in
193 telogen (P63) (**Fig. 3C, 3D left panel**). CD34 and K15 are specifically expressed in the
194 inner and outer layers of the club hair, respectively, and are commonly used to label
195 hair follicle stem cells (30). The whole-mount immunostaining against CD34 and K15
196 revealed that wild-type HFs developed a two-bulge architecture, whereas
197 *Adam17^{D647N/D647N}* mice usually had only one (**Fig. 3D right panel, 3E-F**).

198 At telogen, both wild-type and mutant bulge cells consisted of a $\alpha 6$ integrin (ITGA6)-
199 rich basal layer and an ITGA6-low suprabasal layer, both of which were CD34-positive.
200 Adam17^{D647N/D647N} follicles displayed fewer CD34 positive bulge cells by fluorescence-
201 activated cell sorting (FACS) than wild-type follicles (**Fig. 3G upper panel**).
202 Adam17^{D647N/D647N} follicles displayed lower Ki67 positive than wild-type follicles (**Fig.**
203 **3G lower panel**). Immunofluorescence of CD200, the marker of secondary hair germ
204 (SHG), confirmed a decreased differentiation of HFSCs in Adam17^{D647N/D647N} mice at
205 early stage of anagen (P21) (**Fig. 3H**). Taken together, we find that the *Adam17*
206 (p.D647N) mutation leads to HFSCs abnormalities.

207 ***ADAM17* (p.D647N) mutation decreases its protein stability owing to the enhanced**
208 **auto-ubiquitination.**

209 To elucidate the potential impact of the p.D647N mutation on ADAM17, we
210 analyzed its expression in human subjects and mice samples. Notably, our
211 investigations revealed a significant reduction of ADAM17 protein levels in affected
212 individuals compared to healthy controls (**Fig. 4A-B**), although we did not observe any
213 significant differences in *ADAM17* mRNA levels (**Fig. 4C**). Correspondingly, we
214 observed a decrease in the protein level of Adam17, instead of mRNA levels, in hair
215 follicles of Adam17^{D647N/D647N} mice (**Fig. 4D-F**). We postulated that this might be
216 attributable to the differential stability of two proteins, as mRNA levels could not
217 account for the difference in protein levels. To investigate the stabilities of two proteins,
218 we stably overexpressed wild-type and mutant ADAM17 in HaCaT cells, an
219 immortalized human keratinocyte line. Cycloheximide chase assays results indicated

220 that the mutant ADAM17 displayed a shorter half-life compared to the wild-type
221 counterpart (**Fig. 4G, Fig. S4A**). Subsequently, we treated HaCaT cells with the
222 proteasome inhibitor MG132 or lysosome inhibitor chloroquine (CQ). Our findings
223 revealed that MG132, but not CQ, deterred the reduction of the mutant ADAM17
224 protein level relative to the wild-type counterpart, suggesting that the ubiquitin-
225 proteasome pathway was involved in the further degradation of the mutant ADAM17
226 expression (**Fig. 4H-I, Fig. S4C and Fig.S4E**). Additionally, we verified that *Adam17*
227 (p.D647N) mutation decreases its protein stability via ubiquitin-proteasome pathway in
228 primary cultured fibroblasts from wildtype and *Adam17^{D647N/D647N}* mice (**Fig. S4B,**
229 **S4D and S4F**). Indeed, hyper-ubiquitination of mutant ADAM17 was observed in
230 HEK293T cells (**Fig. 4J**). In summary, our findings indicate that the mutant ADAM17
231 displays elevated auto-ubiquitination levels, ultimately leading to decreased protein
232 stability and lower abundance.

233 Furthermore, we evaluated the shedding activity of ADAM17 in human skin tissue,
234 as well as in primary cultured mouse skin fibroblast cells and HaCaT cells. Our findings
235 indicated a significant reduction in ADAM17 shedding activity in the skin tissue of
236 patients and primary cultured mouse skin fibroblast cells (**Fig S5A-B**). This reduction
237 may be attributed to a decrease in the expression of ADAM17 (**Fig. 4A-C, Fig S4B**). It
238 is worth noting that we overexpressed wild-type and mutant ADAM17 in HaCaT cells
239 and observed no significant difference in shedding activity between the two groups at
240 identical ADAM17 expression levels (**Fig S5C**). These results suggest that *ADAM17*
241 variant does not impact its shedding activity.

242 ***ADAM17* (p.D647N) mutation reinforces the bond between ADAM17 and its**
243 **specific E3 ubiquitin ligase, TRIM47**

244 E3 ubiquitin ligases exhibit substrate specificity by selectively binding to target
245 proteins, which results in their ubiquitination and subsequent degradation. To gain
246 insight into the molecular mechanisms underlying *ADAM17* (p.D647N) mutation
247 causes reduced protein stability, we set out to identify its E3 ubiquitin ligase by co-
248 immunoprecipitation (co-IP) coupled with mass spectrometry. Through in-depth
249 bioinformatic analysis of potential ADAM17-binding proteins identified, we located
250 RING-E3 ligases TRIM47 as potential interactors of ADAM17 (**Fig. 5A-B, Table S1**).
251 We validated the direct interaction between ADAM17 and TRIM47 using co-IP and
252 pull-down assay (**Fig. 5C-D**). The endogenous association between Adam17 and
253 Trim47 was then confirmed by co-immunoprecipitation assay in the epidermal tissue
254 lysates of mice (**Fig. 5E**). Confocal immunofluorescence revealed that ADAM17 and
255 TRIM47 were co-localized in HaCaT cells, primary cultured mouse skin fibroblasts,
256 and hair follicles of mice (**Fig. 5F-H**). Moreover, Trim47 showed high expression in
257 hair follicle stem cells (**Fig. S6A**). *ADAM17* (p.D647N) mutation strengthened the
258 association between ADAM17 and TRIM47, confirming the mass spectrometry results
259 (**Fig. 5B-G**). Subsequent to the aforementioned validation of direct interaction between
260 ADAM17 and TRIM47, we probed the effect of knockdown/overexpression of
261 TRIM47 in mutant ADAM17 HaCaT cells (**Fig. S6B**). Our results indicated that
262 knockdown of TRIM47 impaired the degradation of the mutant ADAM17 (**Fig. 5I**),
263 while overexpression of TRIM47 accentuated degradation of the mutant ADAM17 (**Fig.**

264 **S6C**). These results indicate that *ADAM17* (p.D647N) mutation reinforces the bond
265 between ADAM17 and TRIM47, ultimately resulting in a reduced protein stability.

266 A computational 3D complex structural model by ZDock based on the X-ray crystal
267 structure from the Protein Data Bank was further generated (**Fig. 5J, left panel**).
268 Docking simulation data from the model demonstrated that amino acids D597, K626,
269 D636, K640, D647, D657, L659, N671, and I672 of ADAM17 form a “hairpin”
270 structure (**Fig. 5J, right upper panel**), and that amino acids F409, K425, Y428, D431,
271 A476, R581, and R582 of TRIM47 form a “hairpin” structure (**Fig. 5J, right lower**
272 **panel**). Based on the 3D complex structure model, it was deduced that these hairpin-
273 like structures were accountable for facilitating their interaction.

274 **ADAM17 deficiency blocks Notch signaling pathway consequently impaired hair** 275 **follicle development.**

276 To explore intrinsic effects resulting from the loss of ADAM17 expression, we
277 performed proteomic analysis on the dorsal skin during the anagen phase (P28).
278 Analysis of differentially expressed proteins (DEPs) revealed that *Adam17* variant led
279 to broad changes in protein levels (**Fig. 6A-B**). Specifically, we detected significant
280 increase in ubiquinone and other terpenoid-quinone biosynthesis (Vkorc1, Coq6, and
281 Coq3), along with the up-regulation of the Adam17-specific E3 ubiquitin ligase Trim47
282 (**Fig. 6A-B, Fig. S6D**). Then we confirmed the up-regulation of TRIM47 in mice skin
283 samples and HaCaT cells (**Fig. S6E-G**). Our study revealed that *Adam17* (p.D647N)
284 mutation markedly affect the proper development and organization of hair follicles.
285 Indeed, significant reductions were observed in proteins related to keratinocyte

286 differentiation, hair follicle morphogenesis (**Fig. 6B**), especially proteins linked to hair
287 shaft and IRS structure (**Fig. 6C**). Furthermore, KEGG pathway enrichment analysis
288 demonstrated decreased activity within structural homeostasis-related pathways,
289 including Notch signaling pathway, and cell adhesion pathway (**Fig. 6D**).

290 Previous research has indicated that ADAM17 can shed TGF α , which in turn activates
291 EGFR signaling in hair follicles (18, 19). Thus, we conducted immunohistochemical
292 staining to examine the influence of *Adam17* variant on the EGFR signaling pathway.
293 Our findings revealed that the *Adam17* variant did not impact the expression of EGFR,
294 as well as the phosphorylation of EGFR at Tyrosine 992 (p-EGFR (Try992)) and
295 Tyrosine 1068 (p-EGFR (Try1068)) in *Adam17*^{D647N/D647N} mice (**Fig. S7**). Given that
296 Notch signaling exerts regulatory effects on the differentiation of HFSCs into specific
297 hair follicle cell types, is it plausible that Notch is the underlying cause of the hair loss
298 phenotype observed in ADAM17 mutant mice? The activity of key molecules in the
299 Notch signaling pathway were investigated in human subjects and mice samples.
300 Ligand-mediated activation induces proteolytic cleavages of Notch and releases the
301 NICD, which enters the nucleus and stimulates transcription of target genes (31). Our
302 findings indicate a significant decrease in the protein level of NICD upon *ADAM17*
303 (p.D647) variant, leading to decreased expression of Notch target genes, including *Hes1*,
304 *Hes5*, *Hey1*, and *Hey2* (**Fig. 7A-B, Fig. S8A-B**). RT-PCR analysis demonstrated that
305 the *Adam17* (p.D647N) mutation resulted in inhibited Notch target gene transcripts in
306 mouse skin (**Fig. 7C**). Immunohistochemistry and immunofluorescence assays revealed
307 a reduced amount of NICD in the hair follicles of mice during anagen (**Fig. 7D-E, Fig.**

308 **S8C**). The nuclear and cytoplasmic protein extraction assays further confirmed that the
309 *ADAM17* (p.D647N) variants effectively inhibited the Notch signaling pathway in
310 keratinocytes. This is supported by the observed reduction in the expression of NICD
311 and its target genes within the cell nucleus (**Fig. 7F**). To further investigate the
312 involvement of the Notch signaling pathway in *Adam17* (p.D647N) mutation induced
313 hair follicle malformation, we overexpressed NICD in primary cultured
314 *Adam17^{D647N/D647N}* mice skin fibroblasts. Our findings indicated that *Adam17*
315 (p.D647N) mutation significantly reduced the proliferation ability of primary
316 fibroblasts, which could be rescued by overexpression of NICD (**Fig. 7G-H, Fig. S8D-**
317 **E**). Collectively, our results confirm the relationship between the *ADAM17* (p.D647N)
318 mutation and Notch activation in hair follicle development (**Fig. 7I**).

319 **Discussion**

320 This study presented compelling evidence for the involvement of ADAM17 in the
321 growth of hair follicles and differentiation of HFSCs, underscoring its significance as a
322 potent molecule in the development of HYPT. Our investigation revealed that *ADAM17*
323 (p.D647N) variant caused HYPT in human subjects, and *Adam17* (p.D647N) mutation
324 mice model successfully emulated sparse and woolly hair observed in HYPT. Moreover,
325 detailed mechanistic investigations demonstrated that *ADAM17* (p.D647N) mutation
326 enhanced the interaction between ADAM17 and its E3 ubiquitin ligase TRIM47,
327 leading to increased auto-ubiquitination and consequent degradation of ADAM17.
328 Then reduced ADAM17 expression led to a decrease in the Notch signaling pathway,
329 ultimately inhibiting the development of hair follicles.

330 Inherited hair loss disorders exhibit clinical and genetic heterogeneity, making it
331 challenging to genotype patients accurately for diagnosis confirmation and genetic
332 counseling. To date, over 14 detailed pathogenic genes of HYPT are reported to link
333 with non-syndromic hypotrichosis, including hereditary hypotrichosis simplex (HHS),
334 Marie Unna hereditary hypotrichosis (MUHH), localized autosomal recessive
335 hypotrichosis (LAH), autosomal dominant woolly hair (ADWH) and autosomal
336 recessive woolly hair (ARWH) (6-8, 32-37) (**Table S2**). HYPT3 and HYPT13 with
337 pathogenic genes at *KRT74* and *KRT71* genes, respectively, were also classified as
338 ADWH subtypes 1 and 2 (7, 8). In this study, we identified a novel subtype of
339 congenital hypotrichosis with woolly hair that we designated ADWH3, caused by a
340 heterozygous mutation in *ADAM17*. Affected females exhibited curly hair resembling
341 steel wool, while males displayed a range of phenotypic severity from limited to
342 complete baldness, notwithstanding the pervasive thinning of body hair. Unlike HHS
343 and LAH, which only affects scalp hair or limits to some areas (36), ADWH3's
344 phenotypes were distinguished by a general scarcity of hair throughout the body.
345 Nonetheless, typical of other forms of HYPT, progressive hair loss with age was also
346 extensive (38, 39). Given the challenges associated with distinguishing this type of
347 disorder from other congenital HYPT, genetic testing assumes critical importance.

348 Although the dominant variant in the *ADAM17* gene causes hypotrichosis with
349 woolly hair in humans, homozygous variants are necessary to observe the phenotype in
350 mice. Notably, the homozygous mice, exhibiting a more severe phenotype than
351 heterozygous patients, characterized by developmental retardation, edema in their

352 extremities, and a significantly high mortality rate during the peri-weaning period. This
353 phenotypic difference is likely due to genetic and biological disparities between mice
354 and humans (40). It is important to note the phenotypes observed in animal models may
355 vary from those observed in humans (41). For instance, HPRT deficiency does not
356 constitute a pathological variant in mice, despite its association with severe Lesch-
357 Nyhan syndrome in human hemizygotes (42, 43). In our study, we found that the
358 heterozygous variant in the *ADAM17* gene impaired stability and exhibited haplo-
359 insufficiency in humans, while heterozygous variants maintained adequate protein
360 levels, potentially averting hair development abnormalities in mice. However, further
361 experimental investigation is necessary to fully understand the underlying mechanism.

362 *ADAM17*, a type I transmembrane protein, is composed of multiple domains.
363 Mutations within these domains can lead to a range of disorders, indicating the
364 sensitivity and delicacy of its structure and function. For instance, mutations in the pro-
365 domain (PD) domain have been identified as a key driver of colorectal cancer (44) and
366 late-onset Alzheimer's disease (10). Compound heterozygous mutations in the
367 membrane proximal domain (MPD) and homozygous deletions in disintegrin domain
368 (MD) result in neonatal inflammatory skin and bowel disease 1 (NISBD1,
369 OMIM#614328) (45, 46). Notably, to date, there are no reported mutations in the highly
370 conserved CANDIS domain. Here, we identified a heterozygous variant in the CANDIS
371 domain of *ADAM17* that caused non-syndromic ADWH3. Further mechanistic
372 investigations revealed that the variant in CANDIS enhanced *ADAM17* susceptibility
373 to ubiquitin-mediated degradation by enhancing its association with E3 ubiquitin ligase

374 TRIM47. Ubiquitination is a critical posttranslational modification that plays a pivotal
375 role in protein degradation via the proteasome (25, 47). Additionally, various
376 posttranslational modifications play a crucial role in the rapid and reversible activation
377 of ADAM17 (48-50). For instance, cytoplasmic phosphorylation of ADAM17 can
378 regulate its activation, as well as rapid transport to the cell surface (51), which provides
379 a mechanism for fine-tuning ADAM17 activity in response to cellular signals. Our
380 studies enriched the understanding of the complex regulatory mechanisms that govern
381 ADAM17 function and highlight the importance of structural conservation within the
382 CANDIS domain.

383 Notch pathway is a highly conserved pathway, which exerts regulatory effects on the
384 differentiation of HFSCs into specific hair follicle cell types and represses their
385 differentiation towards the epidermal cell fate (52). Notch signaling also regulates the
386 skin microbiome and inflammation of HFSCs niche, protecting the hair follicle from
387 inflammatory damage (53). Notch1-deficient mice exhibited a thinner, shorter, and
388 wavy appearance, accompanied by a defect in the hair cuticle (54), which were also
389 observed in Adam17^{D647N/D647N} mice. In addition, we identified a significant decrease
390 in the expression of key molecules associated with the Notch signaling pathway in both
391 patients and Adam17^{D647N/D647N} mice. These finding establish a correlation between
392 ADAM17 and Notch signaling, which has been previously reported in various diseases,
393 including prostate tumors, non-small cell lung carcinoma, hepatocellular carcinoma and
394 diabetic nephropathy (55-57).

395 However, the classical viewpoint suggests ADAM10 directly cleaves the S2 site of

396 Notch1 and produces NICD to take effects (53, 58-61), while ADAM17 can only
397 activate Notch signaling in non-physiological conditions *in vitro* (62-66). ADAM10-
398 Notch signaling axis mediated regulation of host-microbial symbiosis crucially protects
399 HFs from inflammatory destruction. Disruption of this signaling axis leads to skin
400 dysbiosis and hair follicle destruction mediated by innate lymphoid cells (53). However,
401 a recent study illustrated that *FGFR2* variants resulted in the activation of EGFR and
402 Notch signaling pathways, along with ADAM10, in an ADAM17-dependent manner
403 (67). Although the molecular mechanisms underlying the crosstalk between ADAM17
404 and ADAM10 mediated Notch were unknown, it is possibly that aberrant activation of
405 ADAM17/EGFR pathways reduces ADAM10 proteolytic activity or alternatively
406 decreases its substrate accessibility (67). Moreover, ADAM17/EGFR signaling
407 promotes the development of the IRS, which is crucial for hair shaft formation (18).
408 However, our findings demonstrated that *Adam17* variant did not impact the expression
409 or phosphorylation of EGFR in *Adam17^{D647N/D647N}* mice. Based on these, we speculate
410 that the downregulation of Notch signaling observed in our study appears to be a
411 secondary effect resulting from dysfunction in the downstream signaling of ADAM17.
412 Future studies are necessary to investigate whether other signaling pathways also
413 contribute to *ADAMI7* variant mediated hair malformations. Understanding the
414 complex interactions between different signaling pathways and their role in hair follicle
415 development may offer insights into potential therapeutic targets for hair loss and other
416 related disorders.

417 **Conclusions**

418 Collectively, this study offers valuable insights into the post-translational modification
419 of ADAM17, highlighting its pivotal function in hair follicle development and
420 expanding the range of inherited hypotrichosis disorders. Our discoveries reveal new
421 possibilities for therapeutic targets for hair loss.

422 **Methods**

423 **Sex as a biological variable**

424 To ensure the generalizability and relevance of our findings across genders, we included
425 both male and female human participants, as well as male and female mice in our study.
426 However, in the mice portion of the study, sex was not treated as a biological variable
427 due to the absence of observed sex-specific differences in any of the measured
428 endpoints between male and female mice.

429 **Whole-exome sequencing analysis and pathogenic gene identification**

430 Whole-exome sequencing analysis and pathogenic gene identification were performed
431 using patient's blood as described previously (68). Comprehensive sequencing data
432 analysis was performed based on autosomal dominant inheritance. Genome-wide
433 linkage analysis was performed with a total of 5789 SNP markers; their average genetic
434 and physical distance were 436 kb and 0.56 cM respectively. In the linkage analysis,
435 we removed SNPs with a call rate less than 90% monomorphic SNPs, and non-
436 Mendelian transmitted markers, and retained a total number of 4532 informative
437 autosomal SNPs. Multipoint parametric linkage analyses were performed using the
438 MERLIN program version 1.1.2. A fully penetrant autosomal-dominant model was
439 used with a rare disease frequency of 0.0001. Critical recombination events of the

440 pedigree members were determined through haplotype construction in MERLIN.

441 **Generation of *Adam17* (p.D647N) mutation mice**

442 *Adam17* (p.D647N) mutation mice were generated using CRISPR/Cas9-mediated
443 genome engineering (Cyagen Biosciences (Suzhou), China). To introduce the desired
444 mutation, a gRNA targeting the mouse *Adam17* gene, a donor oligo carrying the
445 p.D647N (GAC to AAC) mutation, a synonymous mutation (p. R651= (CGA to AGG)),
446 and Cas9 were co-injected into fertilized mouse eggs, resulting in targeted knock-in
447 offspring. F0 founder animals were identified by PCR and subsequent sequence
448 analysis. The founder animals were then bred to wild-type mice to assess germ line
449 transmission and F1 animal generation. Heterozygous F1 mice were intercrossed to
450 generate F2 mice. To identify *Adam17* mutant mice, genomic tail DNA was isolated
451 and subjected to routine genotyping by PCR and subsequent sequence analysis. The
452 primers utilized for PCR and Sanger sequencing are provided in **Table S3**. All animals
453 were group-housed under normal light-dark cycle with food and water ad libitum.

454 **Cell culture**

455 HaCaT cell lines were purchased from Chinese Academy of Sciences Shanghai Branch
456 Cell Bank (China). Cells were cultured in Dulbecco's modified Eagle's medium
457 (DMEM) (Gibco, USA), which was supplemented with 10% fetal bovine serum (Gibco,
458 USA) and 1% penicillin-streptomycin (Gibco, USA).

459 **Tyramide signal amplification (TSA) multiple immunofluorescence assay**

460 TSA multiple immunofluorescences staining experiments were conducted following

461 the manufacturer's instructions (Shanghai Recordbio Technology, China). Paraffin-
462 embedded skin sections were hydrated sequentially in xylene and gradient ethanol.
463 Sections underwent antigen retrieval with a citrate repair buffer at pH 6.0, and blocked
464 with 10% horse serum in PBS at room temperature for 1 h using 10% horse serum in
465 PBS. Primary antibody was added to the sections and incubated overnight at 4°C. After
466 that, horseradish peroxidase (HRP)-conjugated secondary antibodies were added and
467 incubated at room temperature for 1 hour. Finally, the sections were incubated with
468 indicated tyramide fluorescent dyes for 15 minutes at room temperature to complete the
469 fluorescence staining of multiple antibodies. Repeat the above steps starting from the
470 antigen retrieval step for the next primary antibody. The antibodies and their dilutions
471 used in this study were listed in **Table S4**.

472 **Flow cytometry**

473 Skin epidermal cell suspensions were obtained from defined areas of back skin. Skin
474 was minced and incubated overnight in Hank's Balanced Salt Solution buffer (Thermo
475 Fisher Scientific, USA) containing 5 mg/ml Dispase II (Yeasen, China). Next day, the
476 separated epidermal tissue was added to 0.05% trypsin (Thermo Fisher Scientific, USA)
477 with 100 µg/mL DNase I (Sigma-Aldrich, USA) and agitated for 10 minutes. Thereafter,
478 suspension cells were passed through a 75-µm sieve (Millipore, Germany), and
479 sequentially stained with Fixable Viability Dye eFluor 455UV, anti-CD34 eFluor 660,
480 and anti-ITGA6 PE, and anti-Ki67 FITC antibodies. Data were acquired using a BD
481 LSRFortessa X-20 (BD, USA) instrument and analyzed on FlowJo software (FlowJo,
482 USA).

483 **Western blot**

484 Total protein was extracted from cells and tissues by using RIPA lysis buffer, and then
485 subjected to separation using sodium dodecyl sulfate-polyacrylamide gel
486 electrophoresis (SDS-PAGE) and subsequently electro-transferred onto a
487 polyvinylidene difluoride (PVDF) membrane (Millipore, Germany), in accordance with
488 previously established protocols (69). Thereafter, the membrane was blocked with 3%
489 BSA at room temperature for 60 minutes, and then incubated overnight with primary
490 antibodies as indicated. Following this, the membrane was incubated with secondary
491 antibodies for 1.5 hours. The details of the antibodies and their respective dilutions used
492 in this study are provided in **Table S4**.

493 **Quantitative real time PCR (RT-PCR)**

494 Total RNA was extracted from mouse skin or cells using the RNeasy kit, following the
495 manufacturer's instructions. The mRNA was reverse-transcribed into cDNA using the
496 PrimeScript RT Reagent kit (Takara, Japan). Gene expression was quantified in real-
497 time using the SYBR Premix Ex Taq kit (Takara, Japan) on a Quantstudio3 (Applied
498 Biosystems, USA) according to the manufacturer's protocols. Primers used for RT-
499 PCR are provided in **Table S3**. Relative expression was normalized for levels of β -actin.

500 ***In vivo* ubiquitination assays**

501 HEK293T cells were transfected with His-tagged ubiquitin and indicated plasmids.
502 After 24 hours, MG-132 (MCE, USA) was added for 8 h, followed by cell lysis in
503 immunoprecipitation lysis buffer. The lysates were pre-cleared with protein A/G beads
504 for 3 hours, and the cleared supernatants were incubated with HA-tagged antibodies

505 and protein A/G beads at 4 °C for 16 hours. Following this, the pull-down products
506 were washed three times with IP lysis buffer and detected immunoblotting. The details
507 of the antibodies and their respective dilutions used in this study are provided in **Table**
508 **S2**.

509 **Protein stability and degradation**

510 Cycloheximide chase assays were performed on HaCaT cells seeded into 12-well plates
511 to 80-90% confluency. The following day, cells were treated with 50 µM
512 Cycloheximide (MCE, USA) for 2, 4, 6, 8, and 12 hours, respectively. The cells were
513 then lysed with RIPA lysis buffer and analyzed by western blot.

514 Protein degradation by proteasomes pathway was investigated in HaCaT cells seeded
515 in 12-well plates at 80-90% confluence. The next day, cells were treated with 10 µM
516 MG132 (MCE, USA) for 2, 4, 6, 8, and 12 hours. The cells were then lysed with RIPA
517 buffer and analyzed using Western blotting.

518 Protein degradation by autophagy pathway was investigated in HaCaT cells seeded in
519 12-well plates at 80-90% confluence. The next day, cells were treated with 50 µM
520 Hydroxychloroquine (MCE, USA) for 2, 4, 6, 8, and 12 hours. The cells were then lysed
521 with RIPA buffer and analyzed using Western blotting.

522 **Pull-down assay**

523 His-tagged TRIM47 proteins were expressed in bacterial BL21 cells. Following
524 bacterial lysis, His-tagged TRIM47 was purified using Ni-NTA beads (Thermo Fisher
525 Scientific, USA). To investigate the direct interaction between TRIM47 and ADAM17,
526 purified TRIM47 was incubated with *in vitro*-translated wild-type or mutant ADAM17

527 overnight at 4 °C. After washing with ice-cold buffer, proteins were eluted from the
528 beads and detected by immunoblotting.

529 **Statistics**

530 All data were analyzed statistically using GraphPad Prism Version 8.0 (La Jolla, USA).
531 All results were presented as mean ± SD. Shapiro-Wilk test was performed to check the
532 data distribution. Unpaired two-tailed t-tests or Mann Whitney two-tailed tests were
533 utilized for comparisons between two groups. For comparison among multiple groups,
534 ordinary one-way ANOVA with Dunnett's post hoc or Kruskal-Wallis test followed by
535 Dunn's post hoc was used based on the Gaussian or non-Gaussian distribution of the
536 data. $P < 0.05$ (two-side) was considered statistically significant.

537 **Study approval**

538 This study was approved by Xinhua Hospital, Shanghai Jiaotong University School of
539 Medicine and was conducted in accordance with the Declaration of Helsinki and the
540 Department of Health and Human Services Belmont Report. All animal experiments
541 adhered to the regulations specified in the National Academy of Sciences Laboratory
542 Animal Care and Use Guidelines. Approval for conducting animal studies was obtained
543 from the Animal Studies Committee at Xinhua Hospital Affiliated to Shanghai Jiaotong
544 University School of Medicine.

545 **Data availability**

546 The datasets supporting the conclusions of this article are included within the article
547 and its additional files. All supporting data values pertinent to the main manuscript and
548 supplementary materials, including numerical values for all data points depicted in

549 graphs and the underlying values for any reported means, were comprehensively
550 included in the supporting data values file. In this study, the produced data sets are
551 available in the following databases: The mass spectrometry proteomics data and
552 protein interaction AP-MS data have been submitted to the ProteomeXchange
553 Consortium (<https://proteomecentral.proteomexchange.org>) via the iProX partner
554 repository, with the dataset identifiers PXD049458 and PXD049459, respectively.
555 Human variations data have been submitted to CNGB Sequence Archive (CNSA)
556 (<https://db.cngb.org/cnsa/>) with the dataset identifiers sub052490.

557 **Author's contributions**

558 XW and ML designed and conceived this project developed methodology. XW, CP, QZ,
559 WH, KZ, YW, AZ, QC and FC performed experiments and generated data. JW, LZ and
560 CW conducted collection of clinical patient data and relevant specimens. XW, PS, WC,
561 HL and GL analyzed and interpreted data. XW and CP wrote the draft. ML, SZ, ZY and
562 HZ revised and finalized the manuscript. All authors contributed to and approved the
563 manuscript. The order of co-first authors is determined based on the contributions of
564 each author.

565 **Acknowledgments**

566 This work was supported by grants from the National Natural Science Foundation of
567 China (82073422, 82273504 and 82303990), Shanghai Municipal Natural Science
568 Foundation (22YF1427100, 22ZR1440800, and 20ZR1434900), Medical Engineering
569 Cross Research Foundation of Shanghai Jiaotong University (YG2022ZD010,
570 YG2022QN040) and Clinical Research Plan of SHDC (SHDC22022302). We greatly

571 appreciate the patients and their relatives for their participation in this study. We thank
572 the Core Facility of Basic Medical Sciences, Shanghai Jiaotong University School of
573 Medicine for LC–MS/MS and Transmission electron microscopy analyzing.

574 **Conflict of interest**

575 The authors have declared that no conflict of interest exists.

576 **References**

- 577 1. Chen CL, Huang WY, Wang EHC, Tai KY, and Lin SJ. Functional complexity
578 of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for
579 hair regeneration. *Journal of biomedical science*. 2020;27(1):43.
- 580 2. Singam V, Patel KR, Lee HH, Rastogi S, and Silverberg JI. Association of
581 alopecia areata with hospitalization for mental health disorders in US adults.
582 *Journal of the American Academy of Dermatology*. 2019;80(3):792-4.
- 583 3. Prendke M, Kanti-Schmidt V, Wilborn D, Hillmann K, Singh R, Vogt A, et al.
584 Quality of life in children and adolescents with alopecia areata-A systematic
585 review. *Journal of the European Academy of Dermatology and Venereology :
586 JEADV*. 2023.
- 587 4. Toussi A, Barton VR, Le ST, Agbai ON, and Kiuru M. Psychosocial and
588 psychiatric comorbidities and health-related quality of life in alopecia areata: A
589 systematic review. *Journal of the American Academy of Dermatology*.
590 2021;85(1):162-75.
- 591 5. Wasif N, Naqvi SK, Basit S, Ali N, Ansar M, and Ahmad W. Novel mutations
592 in the keratin-74 (KRT74) gene underlie autosomal dominant woolly
593 hair/hypotrichosis in Pakistani families. *Human genetics*. 2011;129(4):419-24.
- 594 6. Wen Y, Liu Y, Xu Y, Zhao Y, Hua R, Wang K, et al. Loss-of-function mutations
595 of an inhibitory upstream ORF in the human hairless transcript cause Marie
596 Unna hereditary hypotrichosis. *Nature genetics*. 2009;41(2):228-33.
- 597 7. Shimomura Y, Wajid M, Petukhova L, Kurban M, and Christiano AM.
598 Autosomal-dominant woolly hair resulting from disruption of keratin 74
599 (KRT74), a potential determinant of human hair texture. *American journal of
600 human genetics*. 2010;86(4):632-8.
- 601 8. Fujimoto A, Farooq M, Fujikawa H, Inoue A, Ohyama M, Ehama R, et al. A
602 missense mutation within the helix initiation motif of the keratin K71 gene
603 underlies autosomal dominant woolly hair/hypotrichosis. *The Journal of
604 investigative dermatology*. 2012;132(10):2342-9.
- 605 9. Scheller J, Chalaris A, Garbers C, and Rose-John S. ADAM17: a molecular
606 switch to control inflammation and tissue regeneration. *Trends in immunology*.
607 2011;32(8):380-7.

- 608 10. Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, et al. A rare loss-of-
609 function variant of ADAM17 is associated with late-onset familial Alzheimer
610 disease. *Molecular psychiatry*. 2020;25(3):629-39.
- 611 11. Tang BY, Ge J, Wu Y, Wen J, and Tang XH. The Role of ADAM17 in
612 Inflammation-Related Atherosclerosis. *Journal of cardiovascular translational
613 research*. 2022;15(6):1283-96.
- 614 12. Song Y, Jo S, Chung JY, Oh Y, Yoon S, Lee YL, et al. RNA interference-
615 mediated suppression of TNF- α converting enzyme as an alternative anti-TNF-
616 α therapy for rheumatoid arthritis. *Journal of controlled release : official journal
617 of the Controlled Release Society*. 2021;330:1300-12.
- 618 13. Gao MQ, Kim BG, Kang S, Choi YP, Yoon JH, and Cho NH. Human breast
619 cancer-associated fibroblasts enhance cancer cell proliferation through
620 increased TGF- α cleavage by ADAM17. *Cancer letters*. 2013;336(1):240-6.
- 621 14. Pelullo M, Nardoza F, Zema S, Quaranta R, Nicoletti C, Besharat ZM, et al.
622 Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal
623 Cancer Progression and Chemoresistance. *Cancer research*. 2019;79(21):5575-
624 86.
- 625 15. Bolik J, Krause F, Stevanovic M, Gandraß M, Thomsen I, Schacht SS, et al.
626 Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks
627 metastasis. *The Journal of experimental medicine*. 2022;219(1):e20201039.
- 628 16. Murthy A, Shao YW, Narala SR, Molyneux SD, Zúñiga-Pflücker JC, and
629 Khokha R. Notch activation by the metalloproteinase ADAM17 regulates
630 myeloproliferation and atopic barrier immunity by suppressing epithelial
631 cytokine synthesis. *Immunity*. 2012;36(1):105-19.
- 632 17. Franzke CW, Cobzaru C, Triantafyllopoulou A, Löffek S, Horiuchi K,
633 Threadgill DW, et al. Epidermal ADAM17 maintains the skin barrier by
634 regulating EGFR ligand-dependent terminal keratinocyte differentiation. *The
635 Journal of experimental medicine*. 2012;209(6):1105-19.
- 636 18. Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, and Aoki J. LPA-
637 producing enzyme PA-PLA α regulates hair follicle development by
638 modulating EGFR signalling. *The EMBO journal*. 2011;30(20):4248-60.
- 639 19. Nagao K, Kobayashi T, Ohyama M, Akiyama H, Horiuchi K, and Amagai M.
640 Brief report: requirement of TACE/ADAM17 for hair follicle bulge niche
641 establishment. *Stem cells (Dayton, Ohio)*. 2012;30(8):1781-5.
- 642 20. Dou S, Li G, Li G, Hou C, Zheng Y, Tang L, et al. Ubiquitination and
643 degradation of NF90 by Tim-3 inhibits antiviral innate immunity. *eLife*.
644 2021;10:e66501.
- 645 21. Liang Q, Tang C, Tang M, Zhang Q, Gao Y, and Ge Z. TRIM47 is up-regulated
646 in colorectal cancer, promoting ubiquitination and degradation of SMAD4.
647 *Journal of experimental & clinical cancer research : CR*. 2019;38(1):159.
- 648 22. Ji YX, Huang Z, Yang X, Wang X, Zhao LP, Wang PX, et al. The
649 deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
650 *Nature medicine*. 2018;24(2):213-23.
- 651 23. Li L, Yu Y, Zhang Z, Guo Y, Yin T, Wu H, et al. TRIM47 accelerates aerobic

- 652 glycolysis and tumor progression through regulating ubiquitination of FBP1 in
653 pancreatic cancer. *Pharmacological research*. 2021;166:105429.
- 654 24. Chen JX, Xu D, Cao JW, Zuo L, Han ZT, Tian YJ, et al. TRIM47 promotes
655 malignant progression of renal cell carcinoma by degrading P53 through
656 ubiquitination. *Cancer cell international*. 2021;21(1):129.
- 657 25. Morreale FE, and Walden H. Types of Ubiquitin Ligases. *Cell*.
658 2016;165(1):248-.e1.
- 659 26. Qian Y, Wang Z, Lin H, Lei T, Zhou Z, Huang W, et al. TRIM47 is a novel
660 endothelial activation factor that aggravates lipopolysaccharide-induced acute
661 lung injury in mice via K63-linked ubiquitination of TRAF2. *Signal
662 transduction and targeted therapy*. 2022;7(1):148.
- 663 27. Azuma K, Ikeda K, Suzuki T, Aogi K, Horie-Inoue K, and Inoue S. TRIM47
664 activates NF- κ B signaling via PKC- ϵ /PKD3 stabilization and contributes to
665 endocrine therapy resistance in breast cancer. *Proceedings of the National
666 Academy of Sciences of the United States of America*. 2021;118(35).
- 667 28. Chi W, Wu E, and Morgan BA. Dermal papilla cell number specifies hair size,
668 shape and cycling and its reduction causes follicular decline. *Development
669 (Cambridge, England)*. 2013;140(8):1676-83.
- 670 29. Hsu YC, Pasolli HA, and Fuchs E. Dynamics between stem cells, niche, and
671 progeny in the hair follicle. *Cell*. 2011;144(1):92-105.
- 672 30. Purba TS, Haslam IS, Poblet E, Jiménez F, Gandarillas A, Izeta A, et al. Human
673 epithelial hair follicle stem cells and their progeny: current state of knowledge,
674 the widening gap in translational research and future challenges. *BioEssays :
675 news and reviews in molecular, cellular and developmental biology*.
676 2014;36(5):513-25.
- 677 31. Bray SJ. Notch signalling in context. *Nature reviews Molecular cell biology*.
678 2016;17(11):722-35.
- 679 32. Shimomura Y, Agalliu D, Vonica A, Luria V, Wajid M, Baumer A, et al.
680 APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex.
681 *Nature*. 2010;464(7291):1043-7.
- 682 33. Levy-Nissenbaum E, Betz RC, Frydman M, Simon M, Lahat H, Bakhan T, et al.
683 Hypotrichosis simplex of the scalp is associated with nonsense mutations in
684 CDSN encoding corneodesmosin. *Nature genetics*. 2003;34(2):151-3.
- 685 34. Zhang X, Guo BR, Cai LQ, Jiang T, Sun LD, Cui Y, et al. Exome sequencing
686 identified a missense mutation of EPS8L3 in Marie Unna hereditary
687 hypotrichosis. *Journal of medical genetics*. 2012;49(12):727-30.
- 688 35. Zhou C, Zang D, Jin Y, Wu H, Liu Z, Du J, et al. Mutation in ribosomal protein
689 L21 underlies hereditary hypotrichosis simplex. *Human mutation*.
690 2011;32(7):710-4.
- 691 36. Pasternack SM, Refke M, Paknia E, Hennies HC, Franz T, Schäfer N, et al.
692 Mutations in SNRPE, which encodes a core protein of the spliceosome, cause
693 autosomal-dominant hypotrichosis simplex. *American journal of human
694 genetics*. 2013;92(1):81-7.
- 695 37. Yu X, Chen F, Ni C, Zhang G, Zheng L, Zhang J, et al. A Missense Mutation

- 696 within the Helix Termination Motif of KRT25 Causes Autosomal Dominant
697 Woolly Hair/Hypotrichosis. *The Journal of investigative dermatology*.
698 2018;138(1):230-3.
- 699 38. Li M, Cheng R, Zhuang Y, and Yao Z. A recurrent mutation in the APCDD1
700 gene responsible for hereditary hypotrichosis simplex in a large Chinese family.
701 *The British journal of dermatology*. 2012;167(4):952-4.
- 702 39. Shimomura Y. Congenital hair loss disorders: rare, but not too rare. *The Journal*
703 *of dermatology*. 2012;39(1):3-10.
- 704 40. Peters LL, Robledo RF, Bult CJ, Churchill GA, Paigen BJ, and Svenson KL.
705 The mouse as a model for human biology: a resource guide for complex trait
706 analysis. *Nature reviews Genetics*. 2007;8(1):58-69.
- 707 41. Searle AG, Edwards JH, and Hall JG. Mouse homologues of human hereditary
708 disease. *Journal of medical genetics*. 1994;31(1):1-19.
- 709 42. Kuehn MR, Bradley A, Robertson EJ, and Evans MJ. A potential animal model
710 for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice.
711 *Nature*. 1987;326(6110):295-8.
- 712 43. Guibinga GH, Hsu S, and Friedmann T. Deficiency of the housekeeping gene
713 hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates
714 neurogenesis. *Molecular therapy : the journal of the American Society of Gene*
715 *Therapy*. 2010;18(1):54-62.
- 716 44. Pavlenko E, Cabron AS, Arnold P, Dobert JP, Rose-John S, and Zunke F.
717 Functional Characterization of Colon Cancer-Associated Mutations in
718 ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and
719 Maturation. *International journal of molecular sciences*. 2019;20(9).
- 720 45. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, et al.
721 Inflammatory skin and bowel disease linked to ADAM17 deletion. *The New*
722 *England journal of medicine*. 2011;365(16):1502-8.
- 723 46. Imoto I, Saito M, Suga K, Kohmoto T, Otsu M, Horiuchi K, et al. Functionally
724 confirmed compound heterozygous ADAM17 missense loss-of-function
725 variants cause neonatal inflammatory skin and bowel disease 1. *Scientific*
726 *reports*. 2021;11(1):9552.
- 727 47. Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and
728 Carcinogenesis. *Trends in biochemical sciences*. 2017;42(4):297-311.
- 729 48. Kubo S, Fritz JM, Raquer-McKay HM, Kataria R, Vujkovic-Cvijin I, Al-Shaibi
730 A, et al. Congenital iRHOM2 deficiency causes ADAM17 dysfunction and
731 environmentally directed immunodysregulatory disease. *Nature immunology*.
732 2022;23(1):75-85.
- 733 49. Li X, Maretzky T, Weskamp G, Monette S, Qing X, Issuree PD, et al. iRhoms 1
734 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling.
735 *Proceedings of the National Academy of Sciences of the United States of*
736 *America*. 2015;112(19):6080-5.
- 737 50. Adu-Amankwaah J, Adzika GK, Adekunle AO, Ndzie Noah ML, Mprah R,
738 Bushi A, et al. ADAM17, A Key Player of Cardiac Inflammation and Fibrosis
739 in Heart Failure Development During Chronic Catecholamine Stress. *Frontiers*

- 740 *in cell and developmental biology*. 2021;9:732952.
- 741 51. Xu P, and Derynck R. Direct activation of TACE-mediated ectodomain
742 shedding by p38 MAP kinase regulates EGF receptor-dependent cell
743 proliferation. *Molecular cell*. 2010;37(4):551-66.
- 744 52. Liu G, Cheng G, Zhang Y, Gao S, Sun H, Bai L, et al. Pyridoxine regulates hair
745 follicle development via the PI3K/Akt, Wnt and Notch signalling pathways in
746 rex rabbits. *Animal nutrition (Zhongguo xu mu shou yi xue hui)*.
747 2021;7(4):1162-72.
- 748 53. Sakamoto K, Jin SP, Goel S, Jo JH, Voisin B, Kim D, et al. Disruption of the
749 endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate
750 lymphoid cell-mediated hair follicle destruction. *Immunity*. 2021;54(10):2321-
751 37.e10.
- 752 54. Vauclair S, Nicolas M, Barrandon Y, and Radtke F. Notch1 is essential for
753 postnatal hair follicle development and homeostasis. *Developmental biology*.
754 2005;284(1):184-93.
- 755 55. Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, et al. Inhibition
756 of Notch pathway arrests PTEN-deficient advanced prostate cancer by
757 triggering p27-driven cellular senescence. *Nature communications*.
758 2016;7:13719.
- 759 56. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, et al. ADAM17
760 regulates epidermal growth factor receptor expression through the activation of
761 Notch1 in non-small cell lung cancer. *Cancer research*. 2010;70(13):5368-78.
- 762 57. Wang R, Li Y, Tsung A, Huang H, Du Q, Yang M, et al. iNOS promotes
763 CD24(+)CD133(+) liver cancer stem cell phenotype through a
764 TACE/ADAM17-dependent Notch signaling pathway. *Proceedings of the
765 National Academy of Sciences of the United States of America*.
766 2018;115(43):E10127-e36.
- 767 58. Weber S, Niessen MT, Prox J, Lüllmann-Rauch R, Schmitz A, Schwanbeck R,
768 et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal
769 integrity and Notch-mediated signaling. *Development (Cambridge, England)*.
770 2011;138(3):495-505.
- 771 59. Pan D, and Rubin GM. Kuzbanian controls proteolytic processing of Notch and
772 mediates lateral inhibition during *Drosophila* and vertebrate neurogenesis. *Cell*.
773 1997;90(2):271-80.
- 774 60. Sotillos S, Roch F, and Campuzano S. The metalloprotease-disintegrin
775 Kuzbanian participates in Notch activation during growth and patterning of
776 *Drosophila* imaginal discs. *Development (Cambridge, England)*.
777 1997;124(23):4769-79.
- 778 61. Rooke J, Pan D, Xu T, and Rubin GM. KUZ, a conserved metalloprotease-
779 disintegrin protein with two roles in *Drosophila* neurogenesis. *Science (New
780 York, NY)*. 1996;273(5279):1227-31.
- 781 62. Alabi RO, Lora J, Celen AB, Maretzky T, and Blobel CP. Analysis of the
782 Conditions That Affect the Selective Processing of Endogenous Notch1 by
783 ADAM10 and ADAM17. *International journal of molecular sciences*.

- 784 2021;22(4).
- 785 63. Bozkulak EC, and Weinmaster G. Selective use of ADAM10 and ADAM17 in
786 activation of Notch1 signaling. *Molecular and cellular biology*.
787 2009;29(21):5679-95.
- 788 64. Groot AJ, Cobzaru C, Weber S, Saftig P, Blobel CP, Kopan R, et al. Epidermal
789 ADAM17 is dispensable for notch activation. *The Journal of investigative*
790 *dermatology*. 2013;133(9):2286-8.
- 791 65. Shimizu H, Hosseini-Alghaderi S, Woodcock SA, and Baron M. Alternative
792 mechanisms of Notch activation by partitioning into distinct endosomal
793 domains. *The Journal of cell biology*. 2024;223(5).
- 794 66. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, et al. A novel
795 proteolytic cleavage involved in Notch signaling: the role of the disintegrin-
796 metalloprotease TACE. *Molecular cell*. 2000;5(2):207-16.
- 797 67. Dixit G, Gonzalez-Bosquet J, Skurski J, Devor EJ, Dickerson EB, Nothnick WB,
798 et al. FGFR2 mutations promote endometrial cancer progression through dual
799 engagement of EGFR and Notch signalling pathways. *Clinical and*
800 *translational medicine*. 2023;13(5):e1223.
- 801 68. Li M, Cheng R, Liang J, Yan H, Zhang H, Yang L, et al. Mutations in POFUT1,
802 encoding protein O-fucosyltransferase 1, cause generalized Dowling-Degos
803 disease. *American journal of human genetics*. 2013;92(6):895-903.
- 804 69. Chen F, Ni C, Wang X, Cheng R, Pan C, Wang Y, et al. S1P defects cause a new
805 entity of cataract, alopecia, oral mucosal disorder, and psoriasis-like syndrome.
806 *EMBO molecular medicine*. 2022;14(5):e14904.

807

808

809

810

811


812

813

814

815

816




818

819 **Fig. 1. ADAM17 variant leads to autosomal dominant hypotrichosis with woolly**
 820 **hair.**

821 (A) Representative clinical pictures of patients with autosomal dominant
 822 hypotrichosis/woolly hair (ADHW). (B) Hematoxylin and eosin (HE) staining of scalp

823 tissues from patients and the normal controls. Scale bars, 125 μm . **(C)** The scanning
824 electron microscope analysis revealed that the patient's hair shaft displayed a non-
825 uniform and abnormal cross-sectional shape. Furthermore, there was a substantial
826 peeling of hair cuticle, which normally functioned as the hair shaft's outermost
827 protective layer. Scale bars, 50 μm . **(D)** Pedigree of the family for patients. Hollow
828 boxes represented the normal male individuals, while solid boxes represented the
829 affected male patients. Hollow circles represented the normal female individuals, while
830 solid circles represented the affected female patients in the family tree. The proband
831 was identified with a black arrow. **(E)** A genome-wide linkage analysis provided
832 evidence of linkage to chromosome 2, with a maximum LOD score of 3.18. **(F)** Gene
833 sequencing revealed the heterozygous *ADAM17* p. Asp647Asn (c.1939G>A) variant in
834 patients. The arrows indicate the variant. **(G)** *ADAM17* was predominantly expressed
835 in the hair cortex, inner root sheath (IRS), and outer root sheath (ORS) of human hair
836 follicle. Scale bar, 500 μm . **(H)** Schematic overview of *ADAM17* protein and its
837 domains. SP, signal peptide; PD, pro-domain; Catalytic, catalytic metalloprotease
838 domain; DD, disintegrin domain; MPD, membrane proximal domain; CANDIS,
839 conserved *ADAM17* seventeen dynamic interaction sequence; TM, transmembrane
840 domain; CD, cytoplasmic domain. The p.D647N mutation was localized in CANDIS
841 domain (indicated by a red arrow). **(I)** Aspartic residue at position 647 is located within
842 the conserved *ADAM17* seventeen dynamic interaction sequence (CANDIS) domain
843 of *ADAM17*, which is highly conserved.




844

845 **Fig. 2. *Adam17* (p.D647N) variant causes abnormal hair follicle morphology and**
 846 **hair loss in mice.**

847 (A) Hair coats and vibrissa hairs of wild-type (WT), *Adam17*^{D647N/+} and

848 *Adam17*^{D647N/D647N} mice at postnatal day (P) 19, P35 and 6 months (M). (B) Pelage hairs

849 were observed under an optical microscope. Left and middle panel: compared with
850 wild-type hairs, all of four hair types of Adam17^{D647N/D647N} pelage hairs showed
851 waviness. Scale bars, 2 mm. Right panel: Adam17^{D647N/D647N} mice displayed a
852 significantly reduced proportion of primary and secondary hairs and a significant
853 increase in the proportion of zigzag hairs. (n = 4 biological replicates). (C) The scanning
854 electron microscope analysis unveiled a significant peeling of the hair cuticle in the hair
855 of Adam17^{D647N/D647N} mice. (D) HE staining revealed a notable structural abnormalities
856 of hair follicles in Adam17^{D647N/D647N} mice at P28. Upper panel scale bars, 250 μ m;
857 lower panel scale bars, 50 μ m; (E) HE staining of longitudinal sections revealed
858 obvious structural abnormalities of hair follicles in Adam17^{D647N/D647N} mice during the
859 first anagen (P7) and second anagen (P28). Scale bars, 250 μ m. (F)
860 Immunofluorescence staining revealed a substantial decrease in IRS markers within the
861 hair follicles of Adam17^{D647N/D647N} mice, suggesting significant morphological
862 abnormalities of the IRS. Scale bar, 100 μ m. (G) A schematic illustration of hair follicle
863 layers and markers expressed in hair follicle. (H) Immunoblot analysis of hair follicle
864 layer-specific markers in dorsal skin. (I) Transmission electron microscopy of hair
865 follicles at approximately 500 μ m depth. Left panel scale bar, 5 μ m; Right panel scale
866 bar, 2 μ m. ORS, outer root sheath; IRS, inner root sheath; Cl, companion layer; He,
867 Henle's layer; Hu, Huxley's layer; Cu, cuticle; Co, cortex; Me, medulla. All
868 experiments were repeated three times. Results were expressed as mean \pm SD; n.s., not
869 significant; * P < 0.05; ** P < 0.01; *** P < 0.001; One-way ANOVA (B).




870

871 **Fig. 3. *Adam17* (p.D647N) variant affects homeostasis of the hair follicle stem cell**
 872 **(HFSCs) niche in hair follicles.**

873 (A) Phenotypes of wild-type, *Adam17*^{D647N/+} and *Adam17*^{D647N/D647N} mice after shaving
 874 back skins during telogen (P19), monitoring initiation of the next hair cycle. *Adam17*
 875 (p.D647N) mutation impeded hair regeneration. (B) Statistical data on the proportion
 876 of the skin with pigmentation in mice after hair shaving. (n = 6 biological replicates).

877 (C) HE staining of back skins during second telogen (P63). Upper panel scale bars, 300
878 μm ; lower panel scale bars, 50 μm . (D-F) Wild-type hair follicles (HFs) possessed a
879 two-bulge architecture, whereas Adam17^{D647N/D647N} HFs usually had only one. (D)
880 Statistical data on the proportion of three hair follicle types. (n = 6 biological replicates).
881 (E) Immunofluorescence was performed on whole-mount back skin hair follicles at the
882 second telogen stage using HFSCs markers K15 and CD34. Scale bar, 100 μm . (F) Skin
883 sections underwent immunofluorescent staining using antibodies specific to HFSCs
884 markers. Scale bars, 40 μm . (G) Fluorescence activated cell sorting (FACS) analyses
885 of HFSCs populations sorted by high $\alpha 6$ -integrin and CD34. Right upper panel:
886 Quantification of CD34 positive/ $\alpha 6$ high cells (indicated by the black square brackets)
887 among epithelial cells in second telogen mice. (n = 4-6 biological replicates). Right
888 lower panel: Quantification of CD34 positive/Ki67positive cells among epithelial cells
889 in second telogen mice. (n = 4-6 biological replicates). (H) HFSCs differentiation was
890 blocked in Adam17^{D647N/D647N} mice. CD200, the marker of secondary hair germ. Scale
891 bars, 40 μm . All experiments were repeated three times. Results were expressed as
892 mean \pm SD; n.s., not significant; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; One-way
893 ANOVA (B, D); Mann-Whitney test (G: Right upper panel); Kruskal-Wallis test (G:
894 Right lower panel).

895



896

897 **Fig. 4. ADAM17 (p.D647N) variant decreases its protein stability owing to**
 898 **enhanced auto-ubiquitination.**

899 (A) Immunohistochemical staining showed that the expression of ADAM17 in patients'

900 hair follicles was significantly lower than that in normal controls. Scale bar, 300 μ m;

901 (n = 8 biological replicates of normal controls; n = 8 technical replicates of patient III:1).

902 **(B)** ADAM17 protein level in the scalp tissues of patients was lower than that in the

903 normal controls. (n = 6 biological replicates of normal controls; n = 6 technical

904 replicates of patient III:1). **(C)** No significant alteration detected in the mRNA levels of

905 *ADAM17*. (n = 4 biological replicates of normal controls; n = 4 technical replicates of

906 patient III:1). **(D)** Adam17 protein level in hair follicles of Adam17^{D647N/D674N} mice was

907 significantly lower than that in wild-type mice. Left scale bar, 100 μ m. Right scale bar,

908 50 μ m. (n = 28-32 technical replicates). **(E)** Adam17 protein level in skin tissues was

909 significantly reduced in Adam17^{D647N/D674N} mice compared to the wild-type mice. (n =

910 3 biological replicates). **(F)** No significant changes were observed in the mRNA levels

911 of *Adam17* between ADAM17^{D647N/D674N} and wild-type mice. (n = 6 biological

912 replicates). **(G)** Cycloheximide (CHX) chase analysis showed that *ADAM17* (p.D674N)

913 mutation induced rapid degradation of ADAM17 in HaCaT cells. **(H)** *ADAM17*

914 (p.D647N) mutation resulted in heightened degradation of ADAM17 through

915 proteasome pathway in HaCaT cells. **(I)** *ADAM17* (p.D647N) mutation had no bearing

916 on the degradation of ADAM17 through the autophagy pathway in HaCaT cells. **(J)**

917 *ADAM17* (p.D647N) mutation resulted in heightened ubiquitination and subsequent


918 degradation of ADAM17 via the proteasomal pathway. All experiments were repeated

919 three times. Results were expressed as mean \pm SD; n.s., not significant; * $P < 0.05$; ** P

920 < 0.01 ; *** $P < 0.001$; Unpaired two-tailed t test (B, C); One-way ANOVA (E, F);

921 Mann-Whitney test (A).

922



924


925 **Fig. 5. TRIM47 is identified as a specific E3 ubiquitin ligase of ADAM17.**

926 (A) LC-MS/MS analysis of wild-type and mutant ADAM17 binding proteins. (B) PSM

927 (peptide spectrum match) score ratios for the proteins identified by mass spectrometry.

928 (C) Co-immunoprecipitation assays indicated that ADAM17 interacts with TRIM47 in
929 HaCaT cells, and their association was enhanced by the *ADAM17* (p.D647N) mutation.
930 HaCaT cells lysates were collected and subjected to co-immunoprecipitation assay
931 using indicated antibodies. (D) The direct interaction between ADAM17 and TRIM47
932 was validated by pull-down assay. *In vitro*-translated ADAM17 was pulled down by
933 purified His tagged-TRIM47 fusion protein. (E) Endogenous association between
934 Adam17 and Trim47 was verified in the epidermal tissue lysates of mice, and *Adam17*
935 (p.D647N) mutation enhanced their association. (F) Confocal immunofluorescence
936 revealed a co-localization (yellow) of ADAM17 (red) and TRIM47 (green) in HaCaT
937 cells, and *ADAM17* (p.D647N) mutation enhanced their co-localization. Scale bars, 8
938 μm (panels 1-3); scale bars, 1 μm (panel 4). (G) Confocal immunofluorescence revealed
939 a co-localization (yellow) of Adam17 (red) and Trim47 (green) in primary cultured
940 mouse skin fibroblasts. Scale bars, 10 μm (panels 1-3); scale bars, 1 μm (panel 4). (H)
941 Adam17 and Trim47 co-localized in both IRS and ORS of hair follicles. The white
942 arrows indicated the co-localization (yellow) of Trim47 (green) and Adam17 (red).
943 Scale bars, 40 μm (panels 1- 4); Scale bars, 20 μm (panel 5). (I) Knockdown of *TRIM47*
944 impeded the proteasomal degradation of ADAM17. Left panel: Representative
945 immunoblot images of the ADAM17 and TRIM47 protein levels during CHX chase
946 assays. Right panel: quantification of immunoblotting results corresponding to the left
947 panel. (n = 3 biological replicates). (J) The three-dimensional structure of
948 ADAM17/TRIM47 complex in stereo. Right upper panel: essential amino acids of
949 ADAM17 (blue) which polar contacted to TRIM47 (green) were depicted in atom-

950 colored stick. Right lower panel: residues of TRIM47 (green) which polar contacted to
951 ADAM17 (blue) were depicted in atom-colored stick. All experiments were repeated
952 three times. Results were expressed as mean \pm SD; ns, not significant; * $P < 0.05$;
953 Unpaired two-tailed t test (G).
954



955


956 **Fig.6. ADAM17 variant inhibits hair follicle development through the Notch**
 957 **signaling pathway.**

958 (A) Log₂-fold change in the normalized counts of Proteomics-seq reads of differentially

959 expressed proteins (DEPs) in wild-type and Adam17^{D647N/D647N} mice. (B) Heatmap of

960 DEPs in the indicated mice, annotated for selected proteins. (C) DEPs analysis revealed
961 a substantial decrease of hair shaft and IRS markers in Adam17^{D647N/D647N} mice. (n = 3
962 biological replicates). (D) Pathway enrichment analysis of DEPs revealed marked up-
963 regulation of ubiquinone and other terpenoid-quinone biosynthesis pathways and
964 down-regulation of Notch signaling pathways. Results were expressed as mean ± SD;
965 **P* < 0.05; ***P* < 0.01; ****P* < 0.001; Unpaired two-tailed t test (C).

966



967

968 **Fig.7. ADAM17 (p.D647N) variant affects Notch signaling resulting in HF's**
 969 **malformation.**

970 (A) Effects of ADAM17 (p.D647N) mutation on protein levels of key molecules

971 involved in Notch signaling observed in the skin biopsy of the patient. (B) Adam17

972 (p.D647N) mutation inhibited Notch signaling in the skin tissues of mice. (C) Effects
973 of *Adam17* (p.D647N) mutation on mRNA levels of key molecules involved in Notch
974 signaling observed in the skin tissues of mice. (n = 6 biological replicates). (D)
975 Immunohistochemical staining showed that *Adam17* (p.D647N) mutation led to down-
976 regulation of ADAM17 and Notch intracellular domain (NICD) expression, but not full-
977 length Notch1 in *Adam17*^{D647N/D647N} mice. Scale bar, 250 μ m. (E) Immunofluorescence
978 showed that *Adam17* (p.D647N) mutation led to down-regulation of *Adam17* and Notch
979 intracellular domain (NICD) expression in hair follicle of *Adam17*^{D647N/D647N} mice.
980 Scale bar, 80 μ m. (F) Cellular component separation assay showed that NICD protein
981 level was decreased in nucleus of ADAM17 mutant HaCaT cells. LaminB2 and a-
982 Tubulin were used as the nuclear, cytosolic protein makers, respectively. (G-H)
983 Overexpressing NICD significantly rescued the proliferation activity of primary
984 fibroblasts derived from *Adam17*^{D647N/D647N} mice. (n = 3 biological replicates). (I)
985 Schematic diagram of Notch signaling pathway. Following sequentially cleaved by
986 ADAM10 and γ -secretase, Notch released its intracellular domain (NICD). NICD then
987 translocated to nucleus, and in collaboration with RBPJ and Mastermind, activated the
988 transcription of target genes including members of the *Hes* and *Hey* families. All
989 experiments were repeated three times. Results were expressed as mean \pm SD; **P* <
990 0.05; ***P* < 0.01; ****P* < 0.001; One-way ANOVA and Kruskal-Wallis test (C);
991 Brown-Forsythe and Welch ANOVA tests (G).